Singapore-based AI-for-science startup ChemLex has secured a US$45 million funding round to build a fully autonomous, AI-driven "self-driving" laboratory for drug discovery and to anchor its global R&D headquarters in Singapore. The announcement underscores the rapid convergence of artificial intelligence, laboratory automation, and high-throughput experimentation in Asia’s pharmaceutical innovation landscape, and positions Singapore more firmly as a regional hub for next-generation drug discovery infrastructure.[4]

The new funding will be used to scale ChemLex’s integrated platform, which combines AI models for molecular design with robotics-enabled synthesis and automated testing workflows. By tightly linking in silico design, automated chemistry, and data feedback loops, ChemLex aims to materially shorten the cycle time from early hit identification to lead optimization, while also enabling pharma and biotech partners to run more experiments with fewer manual interventions. In a region where global and local pharmaceutical companies are racing to improve R&D productivity and reduce risk, this approach directly addresses long-standing bottlenecks in medicinal chemistry and candidate selection.[4]

ChemLex’s "self-driving lab" concept is particularly relevant for B2B pharmaceutical stakeholders, including R&D heads, discovery chemistry leaders, and external innovation teams. Instead of relying purely on traditional contract research organizations (CROs) and manual bench chemists, sponsors will be able to outsource components of their early-stage discovery work to an automated infrastructure that operates with high reproducibility, continuous operation, and dense data capture. For pharma companies pursuing multi-target portfolios, or biotechs with constrained headcount but aggressive timelines, this capability can translate into increased throughput at a lower marginal cost per experiment.[4]

The company is also deepening its strategic collaboration with Singapore’s Experimental Drug Development Centre (EDDC), a government-backed translational drug discovery organization. Through a new memorandum of understanding, EDDC will combine its expertise in target biology, pharmacology, and preclinical development with ChemLex’s AI and automation stack. The shared objective is to compress early drug discovery timelines, de-risk candidate selection decisions, and improve the probability of technical success for programs that may later move into regional or global clinical development.[4]

For pharmaceutical executives evaluating where to allocate discovery budgets or establish satellite R&D nodes, ChemLex’s decision to base its global R&D headquarters and AI laboratory in Singapore sends a broader signal. According to Singapore’s Economic Development Board (EDB), the move exemplifies how the city-state’s deep-tech and biomedical ecosystems can support industrial-scale AI chemistry platforms, from access to talent and compute resources to proximity with multinational pharma regional headquarters. For contract discovery and contract research organizations, this also expands the local ecosystem of partners able to deliver AI-augmented discovery services, potentially enabling hybrid engagement models where traditional wet-lab CROs plug into ChemLex’s automation backbone.[4]

From a supply chain and manufacturing strategy perspective, ChemLex’s platform is explicitly positioned not only for early discovery but also to inform scalable chemistry routes. By integrating AI-driven reaction optimization and automated synthesis, the company states that it can generate more manufacturable routes earlier in the pipeline. This is strategically important for process development teams and CMC (chemistry, manufacturing, and controls) functions, which often have to retrofit synthetic strategies after a clinical candidate is chosen. Earlier visibility on route robustness, reagent availability, and step efficiency can reduce downstream scale-up risk and align with procurement and materials management priorities in Asia-based manufacturing networks.[4]

The funding also reflects investor confidence in AI-native infrastructure for life sciences, as large pharma companies increasingly seek partners that can provide end-to-end, data-centric discovery capabilities rather than point solutions. With rising competition among AI drug discovery vendors globally, ChemLex’s differentiated bet on a physical, highly automated lab in Asia could make it an attractive partner for companies that want both algorithmic innovation and operational execution under one roof. This is particularly relevant for multinational drug makers running regional programs for Asia-specific indications or working with local biotech partners to co-develop assets tailored to Asian patient populations.

Executives in charge of R&D strategy, external innovation, and digital transformation across the pharmaceutical value chain should view ChemLex’s expansion as part of a broader shift. AI-enabled chemistry and autonomous labs are poised to become core infrastructure, much like high-throughput screening and combinatorial chemistry in previous decades. Early adopters among pharmaceutical firms in Asia may gain advantages in speed-to-candidate, portfolio optionality, and data assets that compound over time. For CROs, CMOs, and technology vendors in the region, collaboration opportunities range from integrating analytical equipment and lab robotics into ChemLex’s environment, to co-developing specialized workflows for challenging modalities and complex small molecules.

In the near term, the establishment of ChemLex’s self-driving lab in Singapore is expected to generate demand for advanced laboratory instrumentation, robotics platforms, and cloud-native data management solutions, benefiting suppliers in laboratory automation, analytical equipment, and process informatics. Over the medium term, the platform could become a node in a distributed network of AI-enhanced discovery facilities spanning other Asian innovation centers, further reinforcing the region’s role in global drug discovery outsourcing and contract services. For decision-makers across pharmaceutical R&D, manufacturing planning, and strategic partnerships, this development is a clear signal that the competitive baseline for discovery capabilities in Asia is rising and that AI-plus-automation infrastructure is moving from experimental to operational reality.